Pilot study using Fluorine-18 Sodium Fluoride PET/CT in diagnosing of skeletal metastases in men with prostate cancer.

Pilot study using Fluorine-18 Sodium Fluoride PET/CT in diagnosing of skeletal metastases in men with prostate cancer. - Pilotstudy Sodium Fluoride PET/CT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36047

Enrollment

Registered

2011-10-27

Start date

2012-02-21

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastases spread of cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: De novo prostate cancer, and Informed consent, and indication for bone scintigraphy

Exclusion criteria

Exclusion criteria: oncologic history, and on hormon treatment, and unable to tolerate PET/CT

Design outcomes

Primary

Measure	Time frame
1. Discordance and concordance of NaF PET/CT and bone scan. 2. Sensitivity and specificity of NaF PET/CT for detection of bonemetastases.	—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results